Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: 3βHSD1, ADT, genetic, germline, HSD3B1, profile, response, Treatment | Leave a comment »
It is well understood that some patients exhibit exceptionally good responses to investigational and to standard forms of treatment for cancer — well beyond the responses exhibited by the majority of patients treated with the same type of investigational or standard treatment. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: exceptional, response, Treatment | 1 Comment »
In a rather less that surprising finding, a new paper in the Journal of Clinical Oncology reports that men with existing depressive disorders at the time of diagnosis with prostate cancer “are less likely to undergo definitive treatment and experience worse overall survival.” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: depression, Diagnosis, outcome, response, Treatment | 1 Comment »
The Southwest Oncology Group (SWOG) is very keen to complete the accrual of patients to a small, Phase II, pilot study of the use of abiraterone acetate (Zytiga) in the treatment of men with metastatic prostate cancer and a less than optimal response to standard androgen deprivation therapy (ADT). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, deprivation, response, sub-optimal | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 